Press Releases

Date	Title	View
09/07/21	Summary Toggle Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)	PDF Version
09/01/21	Summary Toggle Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®	PDF Version
08/23/21	Summary Toggle Horizon Therapeutics plc to Participate in Upcoming Conferences	PDF Version
08/04/21	Summary Toggle Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance	Q2 2021 Earnings Release 368.3 KB
07/16/21	Summary Toggle Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™	PDF Version
07/08/21	Summary Toggle Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021	PDF Version
06/30/21	Summary Toggle Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021	PDF Version
06/29/21	Summary Toggle Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus	PDF Version
06/28/21	Summary Toggle Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to FOCUS on Thyroid Eye Disease	PDF Version
06/21/21	Summary Toggle Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout	PDF Version